Enlivex Therapeutics (ENLV) News Today $1.00 -0.01 (-1.32%) As of 02/21/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Enlivex Wins Key Patent in Japan for Osteoarthritis TreatmentFebruary 18, 2025 | tipranks.comEnlivex Therapeutics Ltd: Enlivex Issues Urgent Statement on Fraudulent News DisseminationFebruary 18, 2025 | finanznachrichten.deEnlivex Therapeutics issues statement on ‘fraudulent’ news disseminationFebruary 18, 2025 | markets.businessinsider.comEnlivex Issues Urgent Statement on Fraudulent News DisseminationFebruary 18, 2025 | globenewswire.comEnlivex gains Israeli regulatory approval to commence TMJ osteoarthritis trialDecember 13, 2024 | msn.comEnlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ OsteoarthritisDecember 11, 2024 | globenewswire.comEnlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee OsteoarthritisDecember 5, 2024 | globenewswire.comEnlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee OsteoarthritisDecember 4, 2024 | markets.businessinsider.comEnlivex announces interim efficacy data from Phase I Allocetra trialDecember 4, 2024 | markets.businessinsider.comEnlivex Therapeutics Faces Financial Challenges Amid LossesNovember 29, 2024 | tipranks.comEnlivex Therapeutics adopts Bitcoin treasury reserve strategyNovember 21, 2024 | markets.businessinsider.comEnlivex Therapeutics Ltd. Approves Purchase of Up to $1 Million in Bitcoin as Part of Cash Management StrategyNovember 20, 2024 | quiverquant.comEnlivex Initiates Promising Trial for Psoriatic ArthritisNovember 14, 2024 | markets.businessinsider.comEnlivex completes dosing, follow-up for first patient in study of AllocetraNovember 14, 2024 | markets.businessinsider.comEnlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic ArthritisNovember 14, 2024 | globenewswire.comEnlivex Advances Allocetra Trial for Knee OsteoarthritisNovember 13, 2024 | markets.businessinsider.comEnlivex Therapeutics Reschedules Annual Shareholders MeetingNovember 2, 2024 | markets.businessinsider.comEnlivex Therapeutics receives notice of allowance from Japanese Patent OfficeOctober 31, 2024 | markets.businessinsider.comEnlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with OsteoarthritisOctober 30, 2024 | globenewswire.comBuy Rating Affirmed for Enlivex as Allocetra™ Advances to Phase 2 with Positive Safety and Diverse PipelineSeptember 27, 2024 | markets.businessinsider.comEnlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee OsteoarthritisSeptember 24, 2024 | globenewswire.comEnlivex Buy Rating Affirmed on Strong Clinical and Financial OutlookSeptember 10, 2024 | markets.businessinsider.comEnlivex Therapeutics Ltd. (ENLV.TA)September 2, 2024 | uk.finance.yahoo.comValneva SE (AYJ0.BE)August 21, 2024 | finance.yahoo.comEnlivex Receives Regulatory Authorization For The Initiation Of A Phase I Clinical Trial To Evaluate Allocetra In Patients With Psoriatic ArthritisJuly 23, 2024 | markets.businessinsider.comEnlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TVJuly 19, 2024 | finanznachrichten.deEnlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee OsteoarthritisJune 17, 2024 | globenewswire.comEnlivex Therapeutics Closes up to $15 Million Registered Direct OfferingMay 29, 2024 | globenewswire.comEnlivex Therapeutics Announces up to $15 Million Registered Direct OfferingMay 28, 2024 | globenewswire.comWe're Keeping An Eye On Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn RateMay 21, 2024 | finance.yahoo.comEnlivex CEO Issues Letter to Shareholders – Perspectives on Recent EventsApril 29, 2024 | finance.yahoo.comEnlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee OsteoarthritisApril 22, 2024 | finance.yahoo.comYet Another Biotech Stock Has Found Success During Tuesday's SessionApril 18, 2024 | msn.comEnlivex Therapeutics (ENLV) Price Target Decreased by 41.67% to 7.14April 17, 2024 | msn.comEnlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee OsteoarthritisApril 16, 2024 | finance.yahoo.comEnlivex Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee OsteoarthritisApril 16, 2024 | globenewswire.comEnlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra(TM) In Patients With SepsisApril 13, 2024 | stockhouse.comEnlivex Therapeutics (NASDAQ:ENLV) Price Target Cut to $7.00 by Analysts at HC WainwrightHC Wainwright dropped their price objective on shares of Enlivex Therapeutics from $12.00 to $7.00 and set a "buy" rating on the stock in a research note on Friday.April 12, 2024 | marketbeat.comEnlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with SepsisApril 11, 2024 | finance.yahoo.comEnlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with SepsisApril 11, 2024 | globenewswire.comNasdaq Gains Over 50 Points; US Producer Prices Increase In MarchApril 11, 2024 | msn.comDow Dips 100 Points; CarMax Earnings Miss ViewsApril 11, 2024 | msn.comEnlivex stock plunges 50% on mixed results from sepsis studyApril 11, 2024 | msn.comEnlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With SepsisApril 11, 2024 | globenewswire.comENLV Stock Earnings: Enlivex Therapeutics Misses EPS for Q4 2023April 5, 2024 | msn.comEnlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Up 15.4% in MarchEnlivex Therapeutics Ltd. (NASDAQ:ENLV - Get Free Report) saw a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 261,500 shares, an increase of 15.4% from the February 29th total of 226,600 shares. Based on an average trading volume of 108,300 shares, the days-to-cover ratio is currently 2.4 days.April 2, 2024 | marketbeat.comEnlivex Therapeutics (ENLV) Set to Announce Quarterly Earnings on TuesdayEnlivex Therapeutics (NASDAQ:ENLV) will be releasing earnings on Tuesday, April 2.April 1, 2024 | marketbeat.comEnlivex Therapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TVMarch 22, 2024 | finanznachrichten.deShort Interest in Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Expands By 51.2%Enlivex Therapeutics Ltd. (NASDAQ:ENLV - Get Free Report) was the target of a significant growth in short interest in the month of February. As of February 29th, there was short interest totalling 226,600 shares, a growth of 51.2% from the February 14th total of 149,900 shares. Based on an average trading volume of 104,700 shares, the days-to-cover ratio is presently 2.2 days.March 16, 2024 | marketbeat.comENLV Apr 2024 7.500 callMarch 16, 2024 | finance.yahoo.com Get Enlivex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ENLV and its competitors with MarketBeat's FREE daily newsletter. Email Address ENLV Media Mentions By Week ENLV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ENLV News Sentiment▼0.270.60▲Average Medical News Sentiment ENLV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ENLV Articles This Week▼41▲ENLV Articles Average Week Get Enlivex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ENLV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CTOR News Today GALT News Today INZY News Today ABOS News Today ENTX News Today XFOR News Today CLLS News Today SCLX News Today TARA News Today IGMS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ENLV) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersEx-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. ...Colonial Metals | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredA strange twist 500 miles from WashingtonEnergy is life. And this year, it could also make national heroes out of President Trump and VP Vance. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enlivex Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enlivex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
